- Home
- APGE vs ENOV Comparison
APGE vs ENOV Comparison
Compare APGE & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- ENOV
- Stock Information
- Founded
- APGE 2022
- ENOV 1995
- Country
- APGE United States
- ENOV United States
- Employees
- APGE N/A
- ENOV N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- ENOV Fluid Controls
- Sector
- APGE Health Care
- ENOV Industrials
- Exchange
- APGE Nasdaq
- ENOV Nasdaq
- Market Cap
- APGE 3.0B
- ENOV 2.4B
- IPO Year
- APGE 2023
- ENOV 2008
- Fundamental
- Price
- APGE $37.06
- ENOV $46.59
- Analyst Decision
- APGE Strong Buy
- ENOV Strong Buy
- Analyst Count
- APGE 5
- ENOV 8
- Target Price
- APGE $83.50
- ENOV $67.00
- AVG Volume (30 Days)
- APGE 488.2K
- ENOV 1.2M
- Earning Date
- APGE 03-04-2025
- ENOV 02-20-2025
- Dividend Yield
- APGE N/A
- ENOV N/A
- EPS Growth
- APGE N/A
- ENOV N/A
- EPS
- APGE N/A
- ENOV N/A
- Revenue
- APGE N/A
- ENOV $2,001,668,000.00
- Revenue This Year
- APGE N/A
- ENOV $25.59
- Revenue Next Year
- APGE N/A
- ENOV $5.74
- P/E Ratio
- APGE N/A
- ENOV N/A
- Revenue Growth
- APGE N/A
- ENOV 20.52
- 52 Week Low
- APGE $31.75
- ENOV $38.27
- 52 Week High
- APGE $72.29
- ENOV $65.03
- Technical
- Relative Strength Index (RSI)
- APGE 32.29
- ENOV 58.02
- Support Level
- APGE $36.48
- ENOV $45.02
- Resistance Level
- APGE $42.98
- ENOV $46.34
- Average True Range (ATR)
- APGE 2.92
- ENOV 1.55
- MACD
- APGE -0.99
- ENOV 0.27
- Stochastic Oscillator
- APGE 4.12
- ENOV 76.36
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
About ENOV Enovis Corporation
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention & Recovery (P&R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention & Recovery segment.